







































cinnarizine	 and	 its	 impurity	 were	 determined	 in	 the	 obtained	 ratio	 spectrum	 by	 ratio
difference	method	using	the	difference	between	219.0	and	237.2	nm	and	between	230.0	and
264.0	nm,	respectively.	On	 the	other	hand	dimenhydrinate	could	be	determined	by	dividing
spectrum	 of	 ternary	mixture	 by	 standard	 spectrum	 of	 20	 µg/mL	 of	 cinnarizine	 and	 then	 it
were	 determined	 at	 the	 obtained	 ratio	 spectrum	 by	 ratio	 difference	 method	 using	 the
difference	 between	 216.8	 and	 232.8	 nm.	 Method	 C	 is	 the	 mean	 cantering	 of	 ratio	 spectra
method	 (MCR)	 where	 the	 amplitudes	 at	 234.8,	 240.0	 and	 233.6	 nm	 in	 the	 second	 mean
centering	 ratio	 spectra	were	 used	 for	 determination	 of	 dimenhydrinate,	 cinnarizine	 and	 its















Dimenhydrinate;	 is	 chemically	 known	 as	 8‐chloro‐3,7‐
dihydro‐1,	3‐dimethyl‐1H‐purine‐2,6‐dione	compound	with	2‐
(diphenylmethoxy)‐N,N‐dimethylethanamine	 (1:1),	 it	 is	 the	
diphenhydramine	 salt	 of	 8‐chlorotheophylline	 [1]	 (Figure	 1).	





with	 antihistaminic,	 sedative	 and	 calcium‐channel	 blocking	
activity.	 It	 is	 used	 for	 the	 symptomatic	 treatment	 of	 nausea,	





European	 Pharmacopeia	 (EP)	 [4],	 both	 of	 them	 includes	
potentiometric	titration	for	estimation	of	CIN.	Dimenhydrinate	
is	 official	 in	 BP	 [3],	 EP	 [4]	 and	 United	 States	 Pharmacopeia	
(USP)	 [5],	 which	 includes	 potentiometric	 titration,	 argento‐
metric	titration	and	HPLC	method	for	estimation	of	DMH.	The	












Literature	 review	 shows	 that	 numbers	 of	 analytical	
methods	are	available	 for	estimation	of	both	the	drugs	either	
spectrophotometry	 including:	 Q‐absorbance	 ratio	 spectro‐
photometric	 method	 [6],	 simultaneous	 chemical	 equation	
method	 [7],	 derivative	 spectrophotometric	 method	 [8]	 and	
dual	 wavelength	 spectrophotometric	 method	 [9],	 or	 chro‐
matography	 including:	 validated	 HPTLC	 method	 [10]	 and	
HPLC‐method	[11,12].	
We	 have	 not	 come	 across	 any	 analytical	 methods	 for	
determination	 of	 both	 the	 drugs	 in	 presence	 of	 cinnarizine	
impurity.	 Either	 of	 these	 methods	 can	 be	 used	 for	 determi‐
nation	 of	 cinnarizine	 impurity.	 Therefore,	 the	 objective	 of	
work	 is	 to	 develop	 three	 accurate,	 sensitive	 and	 reliable	
spectrophotometric	 method	 for	 determination	 of	 cinnarizine	
and	dimenhydrinate	 in	presence	of	cinnarizine	 impurity	with	







A	 double	 beam	 UV‐visible	 spectrophotometer,	 Shimadzu,	
Japan,	Model	UV‐1601	PC	with	quartz	cell	of	1	cm	and	UV‐PC	
personal	 software	 version	 3.7	 was	 used.	 The	 spectral	 band	
width	is	2	nm	and	wavelength‐scanning	speed	2800	nm/min.	
Data	analysis	for	mean	centering	of	ratio	spectra	method	was	







Pure	 samples	 of	 CIN	 and	 DMH	 were	 kindly	 supplied	 by	
Amoun	 Pharmaceutical	 Company,	 Cairo,	 Egypt	 with	 claimed	
purity	of	99.6	and	99.7%,	respectively,	according	to	manufac‐
turer	certificates	of	analysis.	While	cinnarizine	impurity	(IMP)	
was	 obtained	 from	 (Sigma‐Aldrich	 Chemie	 GmbH,	 Germany)	





Amocerebral®	 tablets	 (Batch	No.	 6221025030658)	were	
manufactured	 by	 Amoun	 Pharmaceutical	 Company,	 Cairo,	










Stock	 solutions	 of	 CIN,	 DMH	 and	 IMP	 were	 prepared	 in	











Accurate	 aliquots	 equivalent	 to	 30‐300,	 20‐400	 and	 20‐
200	µg	from	CIN,	DMH	and	IMP,	respectively,	were	taken	from	
their	 working	 solutions	 (100	 µg/mL)	 and	 transferred	 into	
three	 separate	 series	 of	 10	 mL	 volumetric	 flasks	 then	
completed	to	 the	mark	with	methanol.	Zero	order	absorption	










Calibration	 curve	of	DMH	was	 constructed	by	plotting	 1D	
amplitudes	at	292.0	nm	(Δλ	=	2	and	scaling	factor	=	10)	versus	
the	corresponding	concentration	 in	 the	 range	of	2‐40	µg/mL.	
For	determination	of	CIN	and	IMP,	the	spectra	of	the	prepared	
samples	 in	 the	 range	 of	 3‐30	 and	 2‐20	 µg/mL,	 respectively,	
were	divided	by	standard	spectrum	of	20	µg/mL	of	DMH,	then	
first	 derivative	 of	 the	 obtained	 ratio	 spectra	 were	 obtained	
using	Δλ	=	2	and	scaling	factor	=	10.	1DD	amplitudes	at	256.2	
and	219.6	nm	were	obtained	from	which	calibration	graphs	for	





For	 determination	 of	 DMH,	 its	 absorption	 spectra	 were	
separately	divided	by	 the	 standard	 spectrum	of	 20	µg/mL	of	
CIN,	 then	 DMH	 was	 determined	 by	 measuring	 the	 ratio	
difference	at	216.8	and	232.8	nm	(at	which	CIN	and	IMP	have	
zero	difference).	While	for	determination	of	CIN	and	IMP	their	
absorption	 spectra	 were	 separately	 divided	 by	 the	 standard	
spectrum	of	20	µg/mL	of	DMH,	 then	CIN	was	determined	by	
measuring	 the	 ratio	 difference	 at	 219.0	 and	 237.2	 nm	 (at	
which	 DMH	 and	 IMP	 have	 zero	 difference).	 While	 IMP	 was	
determined	by	measuring	 the	 ratio	difference	between	230.0	
and	 264.0	 nm	 (zero	 difference	 for	 both	 DMH	 and	 CIN).	 The	
calibration	curves	for	DMH,	CIN	and	IMP	were	constructed	by	
plotting	 the	 ratio	 difference	 (for	 DMH,	 CIN	 and	 IMP)	 at	 the	








of	 CIN;	 the	 recorded	 spectra	 of	 CIN	 were	 divided	 by	 the	
standard	spectrum	of	DMH	(20	µg/mL)	to	obtain	the	first	ratio	
spectra	which	were	 then	mean	 centered.	These	 vectors	were	
then	 divided	 by	 the	 mean	 centered	 ratio	 of	 αIMP/αDMH	
(corresponding	 to	 standard	spectrum	of	20	µg/mL	each)	and	
the	mean	center	of	the	second	ratio	spectra	was	then	obtained.		
By	 the	 same	 way,	 the	 recorded	 spectra	 of	 DMH	 were	
divided	by	the	standard	spectrum	of	20	µg/mL	of	IMP	and	the	
obtained	ratio	spectra	were	then	mean	centered,	these	vectors	
(the	mean	 centered	 ratio	 spectra)	were	divided	by	 the	mean	
centered	 ratio	 of	 αCIN/αIMP	 (corresponding	 to	 standard	
spectrum	of	20	µg/mL	each)	to	obtain	the	second	ratio	spectra	
which	then	mean	centered.		
For	 determination	 of	 the	 IMP,	 the	 scanned	 spectra	 of	 its	
prepared	solutions	were	divided	by	the	standard	spectrum	of	
20	 µg/mL	 of	 DMH	 and	 the	 obtained	 ratio	 spectra	were	 then	
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mean	 centered.	 These	 vectors	 were	 divided	 by	 the	 mean	
centered	 ratio	 of	 αDMH	 /αCIN	 (corresponding	 to	 standard	
spectrum	of	20	µg/mL	each)	and	the	second	ratio	spectra	were	








(in	 the	 ratio	 of	 10‐80%	 of	 CIN)	 were	 prepared.	 The	 volume	
was	completed	with	methanol.	The	procedure	under	 linearity	
for	 each	method	was	 then	 followed	 and	 the	 concentration	 of	












the	 volume	 was	 completed	 with	 methanol	 to	 obtain	 stock	
solution	of	1	mg/mL.	From	which	sample	working	solution	of	





the	 method	 by	 spiking	 the	 pharmaceutical	 formulation	 by	
known	amount	of	standard	drug	powder.	The	recovery	of	the	





Different	 analytical	 methods	 have	 been	 found	 in	 the	
literature	 for	 analysis	 of	 DMH	 and	 CIN	 binary	mixtures.	 But	
these	 methods	 cannot	 be	 applied	 for	 resolving	 the	 ternary	
mixture	 of	 DMH,	 CIN	 and	 IMP.	 As	 previously	 mentioned	 no	
published	 method	 was	 found	 in	 the	 literature	 for	 deter‐
mination	 of	 DMH	 and	 CIN	 in	 presence	 of	 CIN	 impurity.	 The	
work	in	this	manuscript	concerned	with	the	development	and	
validation	 of	 three	 accurate,	 selective	 and	 precise	 spectro‐
photometric	methods	 for	 resolving	 the	overlapped	spectra	of	





There	 are	 many	 factors	 that	 affect	 selectivity	 and	
sensitivity	of	the	developed	methods	such	as:	the	used	solvent,	
the	divisor	concentration	and	the	chosen	wavelength.	Different	
solvents	 were	 tried	 such	 as	 methanol,	 ethanol,	 acetonitrile,	
water,	 0.1	 N	 HCl	 and	 0.1	 N	 NaOH.	 Regarding	 method	 selec‐
tivity,	methanol	was	the	solvent	of	choice.	
Since	 the	 divisor	 and	 its	 concentration	 are	 greatly	 effect	
method	 selectivity,	 so	 different	 divisors	 with	 different	
concentrations	 were	 tried	 using	 of	 standard	 spectrum	 of	 20	
µg/mL	DMH	for	method	A,	B	and	C;	20	µg/mL	CIN	for	method	
B,	C	and	20	µg/mL	IMP	for	method	C	gave	the	best	results.	
Selections	 of	 wavelengths	 play	 important	 rule	 during	
development	 and	 optimization	 of	 method	 B.	 Different	
wavelength	pairs	were	 tested	where	 the	wavelength	pairs	 of	
216.8	and	232.8	nm,	219.0	and	237.4	nm	and	230.0	and	264.0	




In	 this	 method,	 DMH	 could	 be	 determined	 by	 first	
derivative	 (1D)	 spectrophotometric	method	 using	 Δλ	 =	 2	 nm	
and	 scaling	 factor	 =	 10	 then	 measuring	 the	 peak	 amplitude	
values	at	292	nm,	Figure	3.	On	the	other	hand,	the	absorption	
spectra	 of	 different	 concentrations	 of	 CIN	 and	 IMP	 were	
recorded	 in	 the	 wavelength	 range	 of	 200‐400	 nm.	 The	
recorded	spectra	were	divided	by	the	standard	spectrum	of	20	
µg/mL	 DMH	 and	 the	 ratio	 spectra	 were	 obtained,	 then	 first	
derivative	 of	 these	 ratio	 spectra	were	 obtained	 using	 Δλ	 =	 2	
















Calibration	 curves	 relating	 the	 peak	 amplitude	 values	 at	
the	 selected	 wavelength	 versus	 the	 corresponding	
concentration	of	DMH,	CIN	and	IMP	in	the	concentration	range	









where	 Y1,	 Y2	 and	Y3	 are	 peak	 amplitudes	 for	DMH,	CIN	 and	





This	 method	 depended	 on	 using	 the	 ratio	 difference	
method	 which	 has	 the	 same	 principle	 as	 dual	 wavelength	
spectrophotometric	 method.	 The	 principle	 of	 this	 method	 is	
that	 the	 ratio	 difference	 at	 two	 wavelengths	 in	 the	 ratio	
spectra	 is	 directly	 proportional	 to	 the	 concentration	 of	 the	
component	of	interest	where	the	other	components	show	zero	
difference	 at	 the	 selected	 wavelengths.	 Ratio	 difference	


















































Choosing	 of	 wavelength	 pairs	 play	 important	 rule	 in	
method	 selectivity,	 hence	 different	 pairs	 were	 tested.	
Measuring	 the	 difference	 between	 216.8‐232.8	 nm,	 219.0‐
237.2	nm	and	230.0‐264.0	nm	gave	the	best	results.	
The	 absorption	 spectra	 of	 DMH,	 CIN	 and	 IMP	 were	




separately	 divided	 by	 standard	 spectrum	 of	 20	 µg/mL	 DMH	






Figure	 5.	 Division	 spectra	 of	 20	 µg/mL	 of	 each	 of	 cinnarizine	 	,(ـــــ)
dimenhydrinate	 (…)	 and	 impurity	 (‐‐‐)	 using	 standard	 spectrum	 of	 20	
µg/mL	of	cinnarizine	as	a	divisor	and	methanol	as	a	blank.	
	
Calibration	 graphs	 were	 obtained	 by	 plotting	 the	
amplitudes	difference	 at	 the	 selected	wavelengths	versus	 the	














Figure	 6.	 Division	 spectra	 of	 20	 µg/mL	 of	 each	 of	 cinnarizine	 (…),	







and	 ternary	mixtures	 in	 the	 complex	 samples	with	 unknown	











Ratio	of	CIN:DMH	 %	Impurity	 Concentration	taken	(µg/mL)	 %	Recovery	
CIN	 DMH IMP CIN DMH IMP	
Method	A	 	 	 	 	 	 	 	
3:1	 10	 27	 10	 3	 100.97	 101.25	 98.64	
1:2	 30	 14	 40 6 99.84 101.51	 100.04
1:1	 40	 9	 30 6 101.70 98.06 99.69	
1:1	 50	 10	 20 10 101.35 101.59	 101.30
1:1	 70	 6	 20 14 101.12 101.41	 101.50
1:2	 80	 4	 10 16 99.24 98.00 98.26	
Mean±SD	 	 100.14±1.177 99.60±1.404 100.12±1.237
Method	B	 	 	 	
3:1	 10	 27	 10 3 99.36 101.36	 100.26
1:2	 30	 14	 40 6 101.21 99.54 101.11
1:1	 40	 9	 30 6 99.83 99.31 98.66	
1:1	 50	 10	 20 10 99.99 99.45 99.26	
1:1	 70	 6	 20 14 100.78 101.59	 99.80	
1:2	 80	 4	 10	 16	 101.78	 99.31	 100.32	
Mean±SD	 	 99.90±0.863 100.09±1.076 100.49±0.919
Method	C	 	 	 	
3:1	 10	 27	 10 3 100.39 98.13 100.38
1:2	 30	 14	 40 6 99.63 98.26 98.68	
1:1	 40	 9	 30	 6	 101.06	 99.51	 99.39	
1:1	 50	 10	 20	 10	 101.87	 99.23	 101.28	
1:1	 70	 6	 20	 14	 99.34	 100.83	 101.68	
1:2	 80	 4	 10	 16	 98.45	 101.66	 99.43	
Mean	±	SD	 	 99.90±1.331 100.30±1.764 100.70±0.953
	
	




αDMH	 /αIMP	 (corresponding	 to	 standard	 spectrum	 of	 20	
µg/mL	 each)	 and	 the	 mean	 centering	 of	 the	 second	 ratio	
spectra	 was	 then	 obtained.	 By	 the	 same	 way,	 the	 recorded	
spectra	of	DMH	were	divided	by	the	standard	spectrum	of	IMP	
(20	 µg/mL)	 and	 the	 obtained	 ratio	 spectra	 were	 then	mean	
centered,	these	vectors	(the	mean	centered	ratio	spectra)	were	
then	 divided	 by	 the	 mean	 centered	 ratio	 of	 αIMP/αCIN	
(corresponding	 to	 standard	 spectrum	 of	 20	 µg/mL	 each)	 to	
obtain	the	second	ratio	spectra	which	then	mean	centered.	For	
determination	 of	 IMP,	 the	 scanned	 spectra	 of	 its	 prepared	
solutions	were	divided	by	the	standard	spectrum	of	20	µg/mL	
of	 DMH	 and	 the	 obtained	 spectra	 were	 then	mean	 centered.	
These	 vectors	 were	 divided	 by	 the	 mean	 centered	 ratio	 of	
αDMH/αCIN	 (corresponding	 to	 standard	 spectrum	 of	 20	
µg/mL	 each)	 and	 the	 second	 spectra	 ratio	 were	 then	 mean	
centered.	 The	 amplitudes	 of	 the	 second	mean	 centered	 ratio	
spectra	 at	 240.0,	 234.8	 and	 233.6	 nm	 were	 used	 for	
determination	 of	 CIN,	 DMH	 and	 IMP,	 respectively.	 The	
amplitudes	 were	 measured	 and	 plotted	 against	 the	
corresponding	 concentration	 of	 each	 component	 to	 compute	
their	respective	regression	equations	(Figure	7‐9).	Linearity	of	
the	proposed	method	was	evaluated	and	it	was	evident	in	the	
range	 of	 3‐30,	 2‐40	 and	 2‐20	 µg/mL	 for	 CIN,	 DMH	 and	 IMP,	














different	 ratios	 of	 the	 studied	 components,	 where	 the	 mean	
percentage	 recoveries	 for	 DMH,	 CIN	 and	 IMP	 were	
99.60±1.404,	 100.14±1.177	 and	 100.12±1.237,	 respectively,	
for	method	A,	 100.09±1.076,	 99.90±0.863	 and	 100.49±0.919,	










Figure	 8.	 Mean	 centered	 ratio	 spectra	 of	 dimenhydrinate	 (2‐40	 µg/mL)	
using	methanol	as	a	blank.	
	
The	 developed	 spectrophotometric	 methods	 were	 also	
applied	 for	 determination	 of	 CIN	 and	DMH	 in	Amocerebral®	
tablets	 and	 satisfactory	 results	were	 obtained	 (Table	 3).	 The	
validity	 of	 the	 methods	 was	 further	 assessed	 by	 applying	
standard	 addition	 technique	 which	 also	 confirmed	 the	


































Reported	method	[12] Method	CMethod	BMethod	A Parameter 
DMHCIN DMHCINDMHCIN DMH CIN 
103.72 106.16 104.67104.46103.79104.27105.77 103.14 Mean 
1.783 1.747 1.2841.4181.3961.628 1.601 1.079 SD 
3.815 3.664 1.6482.0112.3403.183	2.564	1.164	Variance	
6 6 6666 6 6 N 
‐ ‐0.99361.74250.61331.76961.9861 1.8595 t‐test	a	





calculated	 ones	 confirming	 that	 the	 difference	 between	 the	















The	 linearity	 of	 the	 proposed	methods	was	 evaluated	 by	
analyzing	 different	 concentrations	 of	 CIN,	 DMH	 and	 IMP	 in	
triplicates.	 For	 the	 developed	 methods,	 Beer‐Lambert’s	 was	
obeyed	 in	 the	 range	 of	 3‐30,	 2‐40	 and	 2‐20	 µg/mL	 for	 CIN,	
DMH	 and	 IMP,	 respectively.	 The	 values	 of	 correlation	
coefficients	were	close	 to	unity	 indicating	good	 linearity.	The	
regression	 parameters	 like	 the	 slope,	 intercept	 and	 the	







Accuracy	 of	 the	 proposed	methods	was	 calculated	 as	 the	
percentage	 recoveries	 of	 pure	 samples	 of	 the	 studied	 drugs.	
The	 concentrations	 were	 calculated	 from	 the	 corresponding	
regression	equations,	Table	1.	Accuracy	was	 further	assessed	
by	applying	the	standard	addition	technique	to	Amocerebral®	





Repeatability:	 Three	 concentrations	 7,	 15,	 25	 µg/mL	 of	
CIN;	 20,	 30,	 40	 µg/mL	 of	 DMH	 and	 7,	 12,	 20	 µg/mL	 of	 IMP	
were	 analyzed	 three	 times	 intra‐daily	 using	 the	 proposed	
methods.	 Good	 results	 and	 acceptable	 standard	 deviations	
(SDs)	were	obtained,	Table	1.	
Intermediate	 precision:	 The	 previous	 methods	 were	
repeated	inter‐daily	on	three	different	days	for	the	analysis	of	
the	 chosen	 concentrations.	 Good	 results	 and	 acceptable	 SDs	





Selectivity	 of	 the	 proposed	methods	was	 assessed	 by	 the	
analysis	 of	 different	 synthetic	 laboratory	 prepared	 mixtures	







slope	 were	 used	 for	 determining	 the	 detection	 and	









The	 developed	 methods	 have	 advantages	 over	 the	
published	 methods	 in	 being	 used	 for	 analysis	 of	 cinnarizine	
and	 dimenhydrinate	 in	 the	 presence	 of	 cinnarizine	 impurity.	
These	methods	were	simple,	rapid,	and	cost	effective	and	data	
processing	steps	are	not	time	consuming.	These	spectrophoto‐
metric	 methods	 can	 be	 regarded	 as	 a	 useful	 alternative	 to	
chromatographic	 techniques	 in	 the	 routine	 quality	 control	
analysis	 of	 pharmaceutical	 formulations	 allowing	 rapid	
determination	 at	 relatively	 low	 cost.	 The	developed	methods	
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